Chinese domestic biopharmaceutical companies have become significant competitors in the AS biologic treatment market, with the China Sacroiliitis Treatment Market reflecting the development and commercialization of domestic adalimumab biosimilars, anti-IL-17A antibodies, and JAK inhibitors by Chinese companies that are progressively capturing market share from international originator products...